These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25348770)

  • 1. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ; Schell LK; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007461. PubMed ID: 25348770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2010 Nov; (11):CD007461. PubMed ID: 21069694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Schell LK; Rücker G; Motschall E; Fleeman N; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2014 Jun; 5(5):CD007477. PubMed ID: 24893174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E; Garcia-Manero G; Taher A; Kantarjian HM
    Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
    Tolley K; Oliver N; Miranda E; Migliaccio-Walle K; Bozkaya D; Li Q
    J Med Econ; 2010; 13(3):559-70. PubMed ID: 20812793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
    Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation therapy in myelodysplastic syndromes.
    Fausel CA
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S10-4; quiz S16. PubMed ID: 20332500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
    Sarocchi M; Li J; Li X; Wu D; Montaño Figueroa E; Rodriguez MG; Hou M; Finelli C; Shi HX; Xiao Z; Oliva EN; Gercheva Kyuchukova L; Drummond M; Symeonidis A; Velazquez EJ; Rivoli G; Izquierdo M; Kolekar Y; Spallarossa P; Angelucci E
    Br J Haematol; 2024 May; 204(5):2049-2056. PubMed ID: 38343073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.